Entweder 10000% oder Totalverlust
05.11.02 09:42
#352
Glasnost
12 cent, 13 cent, 14 cent, 13 cent, 12 cent
das entspricht noch nicht so ganz der erwarteten Volatitlität, was meint Ihr?
Glasnost
Glasnost
05.11.02 13:28
#353
grenke
ein riesen T-bon Steak auf Amerikanisch ( 800gr.)
bei Kurse über 50€ natürlich jeden tag.
gruß grenke
gruß grenke
08.11.02 20:36
#354
auf geht´s
von deinen Wunschkursen bist du immer weiter
entfernt, Grenke!!!
Wünsche dir den Reinfall nicht, aber heute ohne Nachrichten -20% ist echt Sch....
Hoher Umsatz bei stark fallenden Kursen - war gut das ich mit kleinem Gewinn raus bin.
Bleibe auch vorerst draußen und kaufe evtl. wieder mal nen Batzen bei 0,08 !
Good luck...
AUF GEHT`S
Wünsche dir den Reinfall nicht, aber heute ohne Nachrichten -20% ist echt Sch....
Hoher Umsatz bei stark fallenden Kursen - war gut das ich mit kleinem Gewinn raus bin.
Bleibe auch vorerst draußen und kaufe evtl. wieder mal nen Batzen bei 0,08 !
Good luck...
AUF GEHT`S
11.11.02 07:32
#355
Eskimato
HIV-Schnelltest zugelassen von der FDA am 08.11.
Allerdings hat Orasure das Rennen gemacht, Pech für CALY-Fans.
Gruss E.
FDA Approves Quick HIV Test
By Associated Press Page 1 of 1
08:13 AM Nov. 08, 2002 PT
The government on Thursday approved a 20-minute HIV test that AIDS experts say is so easy to use it will greatly cut the number of people who unknowingly carry and spread the disease.
It's not the first rapid HIV test. A competing version has been sold since the mid-1990s, but it is so difficult to use that hardly any clinics offer it. Today's routine HIV tests take up to two weeks to provide results and at least 8,000 people a year who test positive at public clinics never return to get the news.
Story Tools
See also
AIDS T-Cell Mystery Solved Twice
Why Some With HIV Are Healthier
New AIDS Drugs Face Curvy Road
Facts, Figures From AIDS Report
Check yourself into Med-Tech
Today's Top 5 Stories
Europeans Outlaw Net Hate Speech
MS: Still a Smartphone Player?
Shrine: Little IMacs Everywhere
Finding Fresh Hope in Fake Fat
FDA Approves Quick HIV Test
The new OraQuick test should slash that number and encourage even more of the almost quarter-million Americans who don't know they're infected to seek testing, federal scientists said Thursday in announcing Food and Drug Administration approval of OraQuick.
This is "a very, very important milestone," said FDA science chief Dr. Murray Lumpkin.
To use OraQuick, a health worker pricks a person's finger, drops a spot of blood into a vial of developing solution and drops in the sticklike testing device.
The dipstick gives results similar to common pregnancy tests: One reddish line means no HIV. Two reddish lines mean the person may be infected and needs a confirmatory test to be sure.
OraQuick at first will be available only in hospitals and large health clinics because of a law that restricts who can use certain types of medical tests.
But the test is so simple that Health and Human Services Secretary Tommy Thompson urged manufacturer OraSure Technologies to seek a waiver of that law allowing OraQuick to be sold in far more places from small doctors' offices to mobile testing vans and maybe even HIV counseling centers staffed by social workers instead of health professionals.
"You don't need a college education to administer the test," said OraSure chief executive Mike Gausling, who said he has begun the paperwork to seek that waiver.
The company, in partnership with Abbott Laboratories, will begin selling OraQuick around year's end. Gausling wouldn't provide an exact price, but said OraQuick should cost less than the $20 it costs to perform old-fashioned laboratory HIV tests.
OraQuick's speed and simplicity mean not only that people don't have to drum up the courage for two clinic visits, but that those facing emergencies can get immediate answers, said Dr. Anthony Fauci of the National Institutes of Health.
For example, women in labor who weren't checked for HIV earlier in pregnancy could get tested in the delivery room. That would let newborns of infected mothers get anti-HIV medication immediately, in hopes of keeping them free of the virus.
Also, doctors and nurses exposed to the blood of patients who might have HIV could learn right away if that person had put them at risk, so they'd know if they needed HIV-blocking medication.
OraQuick also may help when the government begins offering smallpox vaccine to health workers and others as protection against a possible bioterrorist attack. While such vaccine plans aren't final yet, smallpox inoculations pose life-threatening risks to anyone with the AIDS virus so a rapid test could prove critical in screening out potential vaccine recipients who didn't know they had HIV, Fauci said.
Studies show OraQuick is 99.6 percent accurate, the FDA said. People who test positive should get an old-fashioned lab test to confirm HIV infection.
Those who test HIV-free using OraQuick might need to check again a month later if they have recently done anything that could expose them to HIV, such as unprotected sex or intravenous drug use, Lumpkin cautioned. That's because OraQuick detects antibodies to HIV, immune system proteins that can take weeks after infection to form.
AIDS experts expect rapid HIV testing to grow quickly. The FDA is believed close to approving an OraSure competitor, MedMira's Reveal test. OraSure also plans to seek FDA approval soon to use OraQuick to test a swab from a patient's gums instead of blood; OraSure currently sells a lab-based oral HIV test.
AIDS activists have spent the last year pushing FDA to approve the new technology, saying rapid tests could become a standard offering in emergency rooms or homeless shelters spreading access to HIV testing to populations otherwise missed.
"We're excited about it," said Ray Daniels of the National Association of People With AIDS. But he cautioned that clinics still must take the time to properly counsel people about the ramifications of HIV testing before administering OraQuick.
Gruss E.
FDA Approves Quick HIV Test
By Associated Press Page 1 of 1
08:13 AM Nov. 08, 2002 PT
The government on Thursday approved a 20-minute HIV test that AIDS experts say is so easy to use it will greatly cut the number of people who unknowingly carry and spread the disease.
It's not the first rapid HIV test. A competing version has been sold since the mid-1990s, but it is so difficult to use that hardly any clinics offer it. Today's routine HIV tests take up to two weeks to provide results and at least 8,000 people a year who test positive at public clinics never return to get the news.
Story Tools
See also
AIDS T-Cell Mystery Solved Twice
Why Some With HIV Are Healthier
New AIDS Drugs Face Curvy Road
Facts, Figures From AIDS Report
Check yourself into Med-Tech
Today's Top 5 Stories
Europeans Outlaw Net Hate Speech
MS: Still a Smartphone Player?
Shrine: Little IMacs Everywhere
Finding Fresh Hope in Fake Fat
FDA Approves Quick HIV Test
The new OraQuick test should slash that number and encourage even more of the almost quarter-million Americans who don't know they're infected to seek testing, federal scientists said Thursday in announcing Food and Drug Administration approval of OraQuick.
This is "a very, very important milestone," said FDA science chief Dr. Murray Lumpkin.
To use OraQuick, a health worker pricks a person's finger, drops a spot of blood into a vial of developing solution and drops in the sticklike testing device.
The dipstick gives results similar to common pregnancy tests: One reddish line means no HIV. Two reddish lines mean the person may be infected and needs a confirmatory test to be sure.
OraQuick at first will be available only in hospitals and large health clinics because of a law that restricts who can use certain types of medical tests.
But the test is so simple that Health and Human Services Secretary Tommy Thompson urged manufacturer OraSure Technologies to seek a waiver of that law allowing OraQuick to be sold in far more places from small doctors' offices to mobile testing vans and maybe even HIV counseling centers staffed by social workers instead of health professionals.
"You don't need a college education to administer the test," said OraSure chief executive Mike Gausling, who said he has begun the paperwork to seek that waiver.
The company, in partnership with Abbott Laboratories, will begin selling OraQuick around year's end. Gausling wouldn't provide an exact price, but said OraQuick should cost less than the $20 it costs to perform old-fashioned laboratory HIV tests.
OraQuick's speed and simplicity mean not only that people don't have to drum up the courage for two clinic visits, but that those facing emergencies can get immediate answers, said Dr. Anthony Fauci of the National Institutes of Health.
For example, women in labor who weren't checked for HIV earlier in pregnancy could get tested in the delivery room. That would let newborns of infected mothers get anti-HIV medication immediately, in hopes of keeping them free of the virus.
Also, doctors and nurses exposed to the blood of patients who might have HIV could learn right away if that person had put them at risk, so they'd know if they needed HIV-blocking medication.
OraQuick also may help when the government begins offering smallpox vaccine to health workers and others as protection against a possible bioterrorist attack. While such vaccine plans aren't final yet, smallpox inoculations pose life-threatening risks to anyone with the AIDS virus so a rapid test could prove critical in screening out potential vaccine recipients who didn't know they had HIV, Fauci said.
Studies show OraQuick is 99.6 percent accurate, the FDA said. People who test positive should get an old-fashioned lab test to confirm HIV infection.
Those who test HIV-free using OraQuick might need to check again a month later if they have recently done anything that could expose them to HIV, such as unprotected sex or intravenous drug use, Lumpkin cautioned. That's because OraQuick detects antibodies to HIV, immune system proteins that can take weeks after infection to form.
AIDS experts expect rapid HIV testing to grow quickly. The FDA is believed close to approving an OraSure competitor, MedMira's Reveal test. OraSure also plans to seek FDA approval soon to use OraQuick to test a swab from a patient's gums instead of blood; OraSure currently sells a lab-based oral HIV test.
AIDS activists have spent the last year pushing FDA to approve the new technology, saying rapid tests could become a standard offering in emergency rooms or homeless shelters spreading access to HIV testing to populations otherwise missed.
"We're excited about it," said Ray Daniels of the National Association of People With AIDS. But he cautioned that clinics still must take the time to properly counsel people about the ramifications of HIV testing before administering OraQuick.
13.12.02 15:28
#357
Nukem
Ich!
Ich bin aber schon länger drin. Dann dürfte es heute MEGA-FETT abgehen, an der Nasdaq.
13.12.02 15:28
#358
grenke
Meldung von soeben 10 Jahresvertrag 12mio tests ??
hoffe ich habe es richtig gelesen !!!
gruß grenke
Calypte Signs Memorandum of Understanding with the Safe Blood for Africa Foundation
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 13, 2002--
FDA-Approved Urine HIV Antibody Test to be Initiated in African
Blood Bank Settings for Blood Donor Pre-screening Programs
Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that it has executed a Memorandum of Understanding (MOU) with the Safe Blood for Africa Foundation, giving exclusive rights to market and distribute Calypte's urine-based HIV-1 antibody tests in sub-Saharan Africa as a blood donor pre-screening tool. Non-exclusive rights to distribute Calypte's Serum Western Blot tests are also included in the MOU. Provided certain milestones are achieved, it is anticipated that the MOU will become a formal distribution agreement in three months, at which time the agreement will automatically become a ten-year distribution contract. Calypte will donate the first 125,000 Urine EIA tests and train SBFA personnel during the initial three-month MOU period.
The Safe Blood for Africa Foundation is a not-for-profit corporation whose mission is to help prevent the spread of HIV/AIDS throughout 34 countries in sub-Saharan Africa. The organization is working with such groups as the World Bank, USAID, UNAIDS, and the World Health Organization (WHO). The Safe Blood for Africa Foundation estimates that of the 6 million blood transfusions performed annually in sub-Saharan Africa, approximately half of the transfused materials have not been tested for infectious diseases. As the Safe Blood for Africa Foundation's testing responsibility grows to cover all of sub-Saharan Africa, the number of blood transfusions performed is anticipated to grow to 12 million transfusions per year. The Safe Blood for Africa Foundation estimates that less than half of sub-Saharan African countries have adopted a national blood transfusion policy and less than one third of the countries have policies to limit HIV infection through blood transfusions. Since the HIV prevalence in many of these countries exceeds 20%, blood transfusions account for an ever-increasing cause of new infections.
Jeffrey M. Busch, chairman of the Safe Blood for Africa Foundation, stated, "By using this approach, we believe we can accomplish our objective of a safer blood supply in sub-Sahara Africa in a more efficient and cost effective manner. Every dollar saved in unnecessary or duplicative testing processes is a dollar that can be spent expanding our coverage and services. By pre-screening with urine, the Safe Blood for Africa Foundation can either decline the donation outright, or destroy the unit of blood before more money and resources are spent on additional testing."
The MOU with the Safe Blood for Africa Foundation was coordinated with Calypte by Global Business Partners. According to Rick Langley, president of Global Business Partners, "This is an exciting opportunity to work with a product of such universal demand. Calypte's HIV-1 tests can help save thousands of lives by identifying blood donors who have been exposed to HIV while saving valuable healthcare resources for African countries."
"We are excited that the Safe Blood for Africa Foundation is pioneering this approach with our product," stated Nancy Katz, president and chief executive officer of Calypte. "This ingenious approach to blood screening is a cost effective way to reduce the risk of HIV transmission through blood transfusions in regions of the world with high HIV prevalence. Our arrangements with Safe Blood for Africa Foundation hold promise to create a win-win situation for both Calypte and African Blood banks, and we will actively explore expanding similar programs into other high risk regions as we assess the impact of the African effort."
About Calypte
Calypte Biomedical Corporation, headquartered in Alameda, Calif., is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended Dec. 31, 2001 and its subsequent filings with the SEC.
--30--nj/sf*
CONTACT: Calypte Biomedical Corporation
Richard Van Maanen, 510/749-5153
dvanmaanen@calypte.com
or
Lippert/Heilshorn & Associates
Investor Relations:
Brendan Lahiff/Kirsten Chapman, 415/433-3777
brendan@lhai-sf.com
or
Safe Blood for Africa Foundation
Carole Cones, 703/920-5265
gruß grenke
Calypte Signs Memorandum of Understanding with the Safe Blood for Africa Foundation
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 13, 2002--
FDA-Approved Urine HIV Antibody Test to be Initiated in African
Blood Bank Settings for Blood Donor Pre-screening Programs
Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that it has executed a Memorandum of Understanding (MOU) with the Safe Blood for Africa Foundation, giving exclusive rights to market and distribute Calypte's urine-based HIV-1 antibody tests in sub-Saharan Africa as a blood donor pre-screening tool. Non-exclusive rights to distribute Calypte's Serum Western Blot tests are also included in the MOU. Provided certain milestones are achieved, it is anticipated that the MOU will become a formal distribution agreement in three months, at which time the agreement will automatically become a ten-year distribution contract. Calypte will donate the first 125,000 Urine EIA tests and train SBFA personnel during the initial three-month MOU period.
The Safe Blood for Africa Foundation is a not-for-profit corporation whose mission is to help prevent the spread of HIV/AIDS throughout 34 countries in sub-Saharan Africa. The organization is working with such groups as the World Bank, USAID, UNAIDS, and the World Health Organization (WHO). The Safe Blood for Africa Foundation estimates that of the 6 million blood transfusions performed annually in sub-Saharan Africa, approximately half of the transfused materials have not been tested for infectious diseases. As the Safe Blood for Africa Foundation's testing responsibility grows to cover all of sub-Saharan Africa, the number of blood transfusions performed is anticipated to grow to 12 million transfusions per year. The Safe Blood for Africa Foundation estimates that less than half of sub-Saharan African countries have adopted a national blood transfusion policy and less than one third of the countries have policies to limit HIV infection through blood transfusions. Since the HIV prevalence in many of these countries exceeds 20%, blood transfusions account for an ever-increasing cause of new infections.
Jeffrey M. Busch, chairman of the Safe Blood for Africa Foundation, stated, "By using this approach, we believe we can accomplish our objective of a safer blood supply in sub-Sahara Africa in a more efficient and cost effective manner. Every dollar saved in unnecessary or duplicative testing processes is a dollar that can be spent expanding our coverage and services. By pre-screening with urine, the Safe Blood for Africa Foundation can either decline the donation outright, or destroy the unit of blood before more money and resources are spent on additional testing."
The MOU with the Safe Blood for Africa Foundation was coordinated with Calypte by Global Business Partners. According to Rick Langley, president of Global Business Partners, "This is an exciting opportunity to work with a product of such universal demand. Calypte's HIV-1 tests can help save thousands of lives by identifying blood donors who have been exposed to HIV while saving valuable healthcare resources for African countries."
"We are excited that the Safe Blood for Africa Foundation is pioneering this approach with our product," stated Nancy Katz, president and chief executive officer of Calypte. "This ingenious approach to blood screening is a cost effective way to reduce the risk of HIV transmission through blood transfusions in regions of the world with high HIV prevalence. Our arrangements with Safe Blood for Africa Foundation hold promise to create a win-win situation for both Calypte and African Blood banks, and we will actively explore expanding similar programs into other high risk regions as we assess the impact of the African effort."
About Calypte
Calypte Biomedical Corporation, headquartered in Alameda, Calif., is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended Dec. 31, 2001 and its subsequent filings with the SEC.
--30--nj/sf*
CONTACT: Calypte Biomedical Corporation
Richard Van Maanen, 510/749-5153
dvanmaanen@calypte.com
or
Lippert/Heilshorn & Associates
Investor Relations:
Brendan Lahiff/Kirsten Chapman, 415/433-3777
brendan@lhai-sf.com
or
Safe Blood for Africa Foundation
Carole Cones, 703/920-5265
13.12.02 15:33
#360
Nukem
Richtig gelesen! 10 Jahres-Vertrag
Desweiteren ist der Calypte Test der einzig wirklich sichere Urin Test, deshalb auch das FDA Ok!
Ich bin das erste mal bei 3 Euro rein u. zum Zweiten mal bei 30 Cent. Ich werde meine Einstiegskurse wohl bald wieder sehen.
Ich bin das erste mal bei 3 Euro rein u. zum Zweiten mal bei 30 Cent. Ich werde meine Einstiegskurse wohl bald wieder sehen.
13.12.02 15:36
#362
grenke
habe meine ersten bei 16 cent gekauft
durch nachkäufe liege ich jetzt bei ca 9 cent, denke das ich hier mal so richtig absahnen werde.
gruß Grenke
gruß Grenke
14.12.02 10:44
#364
Rambus 9
Na, so toll war´s nun wirklich nicht.
Zwar riesen Umsätze in den USA (Über 9Mio.) aber nur ein lächerliches plus von 4,35%.
Hoffen wir mal, dass der Laden überlebt.
Ein hoffender
Rambus
Hoffen wir mal, dass der Laden überlebt.
Ein hoffender
Rambus
16.12.02 16:58
#365
route132
@grenke
hi grenke, gibt´s was Neues zu Calypte ?
Hab noch ca. 18.000 Stk. im Depot.
gruß hannes
Hab noch ca. 18.000 Stk. im Depot.
gruß hannes
16.12.02 17:06
#367
Nukem
Calypte rennt noch,
Aktuelles Problem ist, daß Calypte neue Aktien auf den Markt gebracht hat. Ich bin weierhin von dem Titel überzeugt. Unbedingt dabeibleiben.
16.12.02 17:36
#368
Glasnost
Wann zum T haben die denn neue Aktien rausgebracht
bei dem Kurs? Kann mir das jemand erklären? die müssen entweder total verzweifelt oder total verblödet sein. Andere kaufen ihre Aktien zurück...
Wann war denn das?
Thanx,
Glasnost
Wann war denn das?
Thanx,
Glasnost
16.12.02 18:40
#369
Quan
Könnte mir mal jemand Helfen mich zu entscheiden!!
wollte etwas Geld in Caly investieren, habe den Tip von nem bekannten bekommen. Ich kann mich aber nicht so richtig entscheiden. Für entscheidunghilfe wäre ich euch sehr dankbar, soll man oder doch lieber wo anders? DANKE!
16.12.02 19:48
#370
Depothalbierer
Wieviele Aktien gibt's von dem Ding?
Nukem , Du sagtest doch , daß die neue Aktien herausgebracht haben.
16.12.02 20:36
#372
Stox Dude
rennt nicht nur CALY hinterher ;-) VXGN heisst
das Baby ;-)
VaxGen INc.
Formed to complete the development of AIDSVAX®, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS
VXGN
$16.25
$ 3.24
24.90% up for today ;-)
Stox Dude
VaxGen INc.
Formed to complete the development of AIDSVAX®, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS
VXGN
$16.25
$ 3.24
24.90% up for today ;-)
Stox Dude
16.12.02 21:11
#373
route132
Wenn sie auf 0,40€ steigen,
sind doch 500% auch nicht von schlechten Eltern. Also warum so geil auf 10.000%.
gruß hannes
gruß hannes